Merck (MRK) to Report New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA® (sitagliptin) & Real-World Evidence Research at ADA Meetings
Tweet Send to a Friend
Merck (NYSE: MRK) today announced that 19 scientific presentations from Merck’s diabetes pipeline and portfolio – including Phase 3 data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
